Using the PEG framework with analyst consensus forward EPS growth of 14.9%, IDEXX Laboratories, Inc. has a fair value of $217.09 based on NTM EPS (FY2026) of $14.56. The current PEG ratio is 2.66.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
PEG works well for steady growers with predictable earnings.
| EPS Growth RateForward | 14.9% |
| Adjusted Growth (clamped 8–25%) | 14.9% |
| Fair P/E | 14.9x |
| NTM EPS (FY2026) | $14.56 |
| Fair Value | $217.09 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $13.08 | — | — |
| FY2026E | $14.56 | +11.3% | 10 |
| FY2027E | $16.45 | +13.0% | 10 |
| FY2028E | $18.75 | +14.0% | 9 |
| FY2029E | $21.45 | +14.4% | 4 |
| FY2030E | $26.21 | +22.2% | 4 |
5Y Forward EPS CAGR: 14.9%
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $744.8M | $8.60 | — |
| FY2022 | $679.1M | $8.03 | -6.6% |
| FY2023 | $845.0M | $10.06 | +25.3% |
| FY2024 | $887.9M | $10.67 | +6.1% |
| FY2025 | $1.1B | $13.08 | +22.6% |
4Y Historical EPS CAGR: 11.1%
The PEG Fair Value uses the Price/Earnings-to-Growth framework. A stock is fairly valued when its P/E ratio equals its earnings growth rate (PEG = 1.0). This model adds dividend yield to the growth rate per the original PEGY formula.
Growth rate priority: analyst consensus forward EPS CAGR (when ≥ 3 analysts cover the stock), falling back to historical EPS CAGR. Using EPS rather than net income avoids distortion from share buybacks. The growth rate is clamped between 8% and 25% — below 8% would undervalue stable earners, while above 25% would overvalue unsustainable spikes.